ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLPT POWR Grades
- CLPT scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.35% of US stocks.
- CLPT's strongest trending metric is Stability; it's been moving down over the last 31 weeks.
- CLPT's current lowest rank is in the Stability metric (where it is better than 13.08% of US stocks).
CLPT Stock Summary
- CLPT's price/sales ratio is 29.19; that's higher than the P/S ratio of 92.13% of US stocks.
- With a year-over-year growth in debt of 59.06%, ClearPoint Neuro Inc's debt growth rate surpasses 87.24% of about US stocks.
- The volatility of ClearPoint Neuro Inc's share price is greater than that of 92.47% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to CLPT, based on their financial statements, market capitalization, and price volatility, are INVE, REKR, ALLT, SILK, and AWH.
- CLPT's SEC filings can be seen here. And to visit ClearPoint Neuro Inc's official web site, go to www.clearpointneuro.com.
CLPT Stock Price Chart Interactive Chart >
CLPT Price/Volume Stats
|Current price||$18.88||52-week high||$31.29|
|Prev. close||$19.31||52-week low||$3.15|
|Day high||$19.37||Avg. volume||407,794|
|50-day MA||$19.04||Dividend yield||N/A|
|200-day MA||$15.23||Market Cap||391.97M|
ClearPoint Neuro, Inc. (CLPT) Company Bio
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.
CLPT Latest News Stream
|Loading, please wait...|
CLPT Latest Social Stream
View Full CLPT Social Stream
Latest CLPT News From Around the Web
Below are the latest news stories about ClearPoint Neuro Inc that investors may wish to consider to help them evaluate CLPT as an investment opportunity.
ClearPoint Neuro, Inc. Announces Installation of ClearPoint® 2.0 Software at Mazowiecki Szpital Bródnowski in Poland
SOLANA BEACH, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the installation of its version 2.0 software at Mazowiecki Szpital Bródnowski in Warsaw, Poland. “We appreciated the patience and commitment of the on-site ClearPoint team throughout the installation process,” stated Professor Mirosław Ząbek, Head of the Neurosurgery Clinic at Mazowiecki Szpital B
SOLANA BEACH, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. The annual Russell indexes reconstitution captures the 4,000 largest U
ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform ClearPoint Neuro ClearPoint Neuro Navigation Platform for Drug Delivery SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, on the dose ad
US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its quarterly report and things are looking bullish. Revenues of...
ClearPoint Neuro, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLPT Price Returns